Keylika

Keylika is an early stage biopharma startup revolutionizing the treatment for Iron Deficiency Anemia (IDA). The company is focused on developing organometallic drugs using a proprietary platform synthesis technology to address unmet medical needs. Keylika's approach involves administering these drugs using proven delivery technologies to achieve the best clinical outcomes. By combining drug discovery and drug delivery, the company can customize the molecular structure and formulation of a drug, as well as the microsystems engineering component, to fit the most clinically advantageous mode of drug delivery. The flagship product of Keylika is a novel iron complex administered through a wearable transdermal patch, which is expected to be a breakthrough therapy for IDA without the gastrointestinal side-effects associated with oral iron supplements or the risks of IV iron infusions. Their initial target market comprises young women of child-bearing age suffering from heavy menstruation or menorrhagia, representing a population of 6 million in the US. The company's solution addresses an understated problem, as iron deficiency affects 30 million people in the US and 1.6 billion worldwide, with suboptimal current solutions. In August 2022, Keylika received Pre Seed Round investment from Y Combinator, and the company has been accepted into the Y Combinator Summer 2022 cohort, commencing in June. With a promising product and the backing of a renowned accelerator, Keylika is poised to make a significant impact in the field of biopharmaceuticals.